This site is intended for healthcare professionals

BeiGene announces that RATIONALE 303 trial of tislelizumab in non-small cell lung cancer met the primary endpoint of overall survival at interim analysis.

Read time: 1 mins
Last updated:18th Nov 2020
Published:18th Nov 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register free for full access to